and in weight and length at 12 and 18 months CA in infants born ≥ 1250 g; reduction in hayfever at either 12 or 18 months CA in male infants, RR 0.15 (0.03, 0.64), $P=0.01$; reduction in supplemental oxygen use at 36 weeks PMA in male infants, RR 0.67 (0.47, 0.96), $p=0.03$ and in all infants < 1250 g; RR 0.75 (0.57, 0.98), $p=0.04$.

Conclusions: DHA supplementation in infants < 33 weeks gestation does not negatively affect growth, reduces bronchopulmonary dysplasia in male infants and in all infants < 1250 g and reduces hayfever in male infants.

146

A RANDOMIZED, DOUBLEBLIND CROSSOVER STUDY COMPARING RHBSSL (RECOMBINANT HUMAN BILESALTSTIMULATED LIPASE) AND PLACEBO ADDED TO INFANT FORMULA IN PRETERM INFANTS

L. Maggio¹, M.P. Bellagamba², S. Costa¹, C. Romagnoli¹, M. Rodriguez³, K. Timdahl⁴, M. Vågerö⁴, V.P. Carnielli²

¹Policlinico 'Agostino Gemelli'- Università Cattolica del Sacro Cuore, Roma, ²Polytechnic University of Marche and Azienda Ospedaliero Universitaria Ospedali Riuniti 'Umberto I-G.M. Lancisi-G. Salesi', Ancona, Italy, ³Dirección General Científica, Laboratorios Ordesa, Barcelona, Spain, ⁴Clinical Development, Swedish Orphan Biovitrum, Stockholm, Sweden

Background: The rationale for enzyme replacement therapy with rhBSSL in preterm infants is to restore the natural lipase activity that is absent when mother's milk is replaced with infant formula or human pasteurized milk.

Objectives: To compare the CFA of total fat and of selected fatty acids, as well as growth and safety in preterm infants treated with 0.15 g/L rhBSSL or placebo. 33 infants with a mean ($\pm$ SD) weight of 1494 ± 195 g and GA 32.6 ± 0.46 weeks were randomised at 3.4 ± 1.19 weeks of life to receive one-week treatment with rhBSSL and placebo in a crossover design. 32 infants completed the study and 26 were evaluable for CFA.

Results: During rhBSSL treatment a small but not statistically significant increase in total CFA (2.1%) was observed as compared to placebo. A statistically significant improvement in weight of 3.7 g/kg/day (95% CI: 1.6 to 5.9) with rhBSSL (mean 18.1 SD 3.96) compared to placebo (mean

14.3 SD 6.49) ($p=0.001$) was observed. There was a trend towards improved intestinal absorption of docosahexanoic acid and arachidonic acid (7.1% and 6.8% respectively) with rhBSSL.

One serious adverse event occurred during the study but was not related to study drug. No difference in tolerability between rhBSSL and placebo was seen.

Conclusion: In this first clinical study of rhBSSL in preterm infants a statistically significant increase in weight gain was observed. After one week of treatment, there was no significant difference in CFA. The safety and tolerability profile of rhBSSL added to formula was similar compared to placebo.

147

BIOCHEMICAL AND NON-INVASIVE BRAIN MONITORING IN NEWBORNS WHOSE MOTHERS USED ANTIDEPRESSANTS DRUGS DURING PREGNANCY

V. Bellissima¹, S. Miriam¹, M. Colivicchi¹, F. Guerriero¹, M. Strozzi¹, T. Ververs², F. van Bel³, D. Gazzolo¹

¹Ospedale Infantile Cesare Arrigo, Alessandria, Italy, ²University Medical Center Utrecht, ³University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands

Background and aims: The use of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRI) during pregnancy is increasing to up 2% of pregnant women. It is been shown both in human and in animal models that SSRI exposure during pregnancy can have side-effects on whole organs including Central Nervous System (CNS). In this regard, tremors, irritability, disturbed sleep regulation, feeding problems, neonatal convulsions and respiratory distress have been reported. Therefore, the present study is aimed at investigating whether the concentration in maternal and neonatal biological fluids of a well-established biochemical marker of brain development and damage, namely S100B protein, can vary according to SSRI exposure.

Methods: An observational study was conducted in 25 pregnant women exposed to SSRI and in 25 healthy pregnancies as controls. S100B protein was measured at different pregnancy time-points (at 26, 30, 34 wks and at delivery) in maternal blood, at delivery in arterial and venous cord blood and at 24-h after birth in newborns.